目的探讨环状RNA circATP2B1对胃癌细胞增殖和侵袭的影响及其可能的分子机制。方法收集2018年7月至2021年2月福建医科大学附属泉州第一医院胃肠肝胆外科行手术切除并病理学诊断的44例胃癌组织标本及癌旁组织标本。选取4株胃癌细胞系(SGC...目的探讨环状RNA circATP2B1对胃癌细胞增殖和侵袭的影响及其可能的分子机制。方法收集2018年7月至2021年2月福建医科大学附属泉州第一医院胃肠肝胆外科行手术切除并病理学诊断的44例胃癌组织标本及癌旁组织标本。选取4株胃癌细胞系(SGC7901、HS-746T、MGC803、BGC823)和正常胃黏膜上皮细胞系(GES-1)。RT-qPCR检测胃癌组织和细胞系中circATP2B1表达。将circATP2B1表达最低的胃癌细胞分为对照组(转染阴性对照质粒)和实验组(转染circATP2B1过表达质粒)。分别采用MTT法和Transwell小室法检测各组胃癌细胞的增殖活性和侵袭能力。生物信息学和双荧光素酶报告基因实验分析circATP2B1可能的作用机制,RT-qPCR和Western blot检测circATP2B1下游基因的表达。结果胃癌组织circATP2B1表达量显著低于癌旁组织(0.92±0.08 vs 3.62±0.23,P<0.01)。胃癌细胞系circATP2B1表达量均显著低于GES-1细胞(P<0.01),其中以HS-746T细胞的表达量最低(P<0.01)。与对照组相比,实验组HS-746T细胞的增殖活性显著降低(P<0.05),侵袭能力显著下降(P<0.01)。生物信息学和双荧光素酶报告基因实验显示circATP2B1可靶向结合miR-452-5p(P<0.01),miR-452-5p可靶向结合原钙黏附蛋白9(PCDH9)(P<0.01)。与对照组比较,实验组HS-746T细胞miR-452-5p表达显著下降(1.00±0.04 vs 0.24±0.05,P<0.01),PCDH9基因表达显著上升(P<0.01)。结论circATP2B1在胃癌组织和细胞系中低表达,circATP2B1通过靶向结合miR-452-5p正调控PCDH9基因表达,进而降低胃癌HS-746T细胞增殖和侵袭能力。展开更多
目的探讨白三烯受体拮抗剂(leukotriene receptor antagonists,LTRA)与ATP结合盒亚家族C1(ATP-binding cassette sub-family C member 1,ABCC1)基因rs119774位点、溶质载体有机阴离子转运蛋白家族成员2B1(solute carrier organic anion ...目的探讨白三烯受体拮抗剂(leukotriene receptor antagonists,LTRA)与ATP结合盒亚家族C1(ATP-binding cassette sub-family C member 1,ABCC1)基因rs119774位点、溶质载体有机阴离子转运蛋白家族成员2B1(solute carrier organic anion transporter family member 2B1,SLCO2B1)基因rs12422149位点的单核苷酸多态性(single nucleotide polymorphism,SNP)治疗汉族儿童支气管哮喘疗效的相关性。方法选取2019年4月至2021年12月于福建中医药大学附属厦门市中医院就诊的4~13岁汉族支气管哮喘患儿100例为研究对象,采用一代测序法对患儿的ABCC1基因rs119774位点、SLCO2B1基因rs12422149位点进行检测,分析比较2个位点的SNP分布情况。入组患儿均应用LTRA进行治疗,分别于治疗前与治疗12周时进行肺通气功能及脉冲震荡功能检测,并评估临床症状控制水平,分析患儿疗效与SNP的相关性。统计学方法采用t检验、χ^(2)检验。结果治疗前与治疗12周后,ABCC1基因rs119774位点CC型哮喘患儿应用孟鲁司特钠第1秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))[(87.0±16.5)与(93.2±15.1)L,t=-2.071,P=0.038]、峰值呼气流速(peak expiratory flow,PEF)[(77.1±16.9)与(86.5±16.6)L/s,t=-3.233,P=0.001]和25%肺活量的呼气流速(forced expiratory flow 25,FEF25)[(69.6±18.8)与(78.1±19.9)L/s,t=-1.985,P=0.047]均有明显提高,脉冲震荡各项指标显著改善(P<0.05)。治疗后SLCO2B1基因rs12422149位点AA型肺功能指标PEF高于治疗前[(79.0±16.0)与(93.0±9.4)L/s,t=-2.547,P=0.011],治疗后GG型肺功能各指标显著高于治疗前(P<0.05)。ABCC1治疗前后控制率[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001];治疗前后SLCO2B1基因rs119774位点AA型、AG型、GG型的控制率分别为[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001]、[53%(8/15)与80%(12/15),93%(14/15)χ^(2)=12.786,P=0.002]与[56%(23/41)与78%(32/41),78%(32/41),χ^(2)=6.583,P=0.037]与[73%(32/44)与77%(34/44),73%(32/44),χ^(2)=6.471,P=0.039],均显著改善。结论LTRA治疗汉族支气管哮喘患儿与ABCC1、SLCO2B1基因SNP的效果存在相关性。展开更多
Fexofenadine is useful in various allergic disease treatment.However,the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking.This study aimed to verify the v...Fexofenadine is useful in various allergic disease treatment.However,the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking.This study aimed to verify the validity of previously proposed genetic factors through fexofenadine population pharmacokinetic modeling and to explore the quantitative correlations affecting the pharmacokinetic variability.Polymorphisms of the organic-anion-transporting-polypeptide(OATP)1B1 and 2B1 have been proposed to be closely related to fexofenadine pharmacokinetic diversity.Therefore,modeling was performed using fexofenadine oral exposure data according to the OATP1B1-and 2B1-polymorphisms.OATP1B1 and 2B1 were identified as effective covariates of clearance(CL/F)and distribution volume(V/F)-CL/F,respectively,in fexofenadine pharmacokinetic variability.CL/F and average steady-state plasma concentration of fexofenadine differed by up to 2.17-and 2.20-folds,respectively,depending on the OATP1B1 polymorphism.Among the individuals with different OATP2B1 polymorphisms,the CL/F and V/F differed by up to 1.73-and 2.00-folds,respectively.Ratio of the areas under the curves following single-and multiple-administrations,and the cumulative ratio were significantly different between OATP1B1-and 2B1-polymorphism groups.Based on quantitative prediction comparison through a model-based approach,OATP1B1 was confirmed to be relatively more important than 2B1 regarding the degree of effect on fexofenadine pharmacokinetic variability.Based on the established pharmacokineticpharmacodynamic relationship,the difference in fexofenadine efficacy according to genetic polymorphisms of OATP1B1 and 2B1 was 1.25-and 0.87-times,respectively,and genetic consideration of OATP1B1 was expected to be important in the pharmacodynamics area as well.This population pharmacometrics study will be a very useful starting point for fexofenadine precision medicine.展开更多
目的:研究肥胖小鼠及正常小鼠不同周龄下丘脑组织SH2B1(adapter protein with a Src-homology 2 domain),细胞因子信号转导抑制蛋白3(the suppressor of cytokine signaling-3,SOCS3),蛋白质酪氨酸磷酸酶1B(proteintyrosine phosphatase...目的:研究肥胖小鼠及正常小鼠不同周龄下丘脑组织SH2B1(adapter protein with a Src-homology 2 domain),细胞因子信号转导抑制蛋白3(the suppressor of cytokine signaling-3,SOCS3),蛋白质酪氨酸磷酸酶1B(proteintyrosine phosphatase 1B,PTP1B)和神经肽Y(neturopetide Y,NPY)表达的变化规律及其与血清瘦素及胰岛素水平的关系。方法:选用健康C57BL/6乳鼠制作肥胖动物模型,计算Lee’s指数及稳态模型胰岛素抵抗指数。荧光定量RT-PCR法检测下丘脑SH2B1,SOCS3及PTP1B mRNA表达量,Western印迹检测下丘脑SH2B1和NPY蛋白表达量。结果:与同周龄对照组小鼠相比,肥胖组小鼠下丘脑组织SH2B1 mRNA表达减少,SOCS3及PTP1B mRNA表达增加;Western印迹结果显示:肥胖组小鼠SH2B1蛋白表达水平较对照组下降,NPY表达升高。直线相关分析显示:血清瘦素和血清空腹胰岛素水平与SH2B1 mRNA表达呈负相关,与SOCS3及PTP1B mRNA表达正相关。结论:SH2B1,SOCS3,PTP1B及NPY是肥胖发生、发展过程中的关键因子。展开更多
文摘目的探讨环状RNA circATP2B1对胃癌细胞增殖和侵袭的影响及其可能的分子机制。方法收集2018年7月至2021年2月福建医科大学附属泉州第一医院胃肠肝胆外科行手术切除并病理学诊断的44例胃癌组织标本及癌旁组织标本。选取4株胃癌细胞系(SGC7901、HS-746T、MGC803、BGC823)和正常胃黏膜上皮细胞系(GES-1)。RT-qPCR检测胃癌组织和细胞系中circATP2B1表达。将circATP2B1表达最低的胃癌细胞分为对照组(转染阴性对照质粒)和实验组(转染circATP2B1过表达质粒)。分别采用MTT法和Transwell小室法检测各组胃癌细胞的增殖活性和侵袭能力。生物信息学和双荧光素酶报告基因实验分析circATP2B1可能的作用机制,RT-qPCR和Western blot检测circATP2B1下游基因的表达。结果胃癌组织circATP2B1表达量显著低于癌旁组织(0.92±0.08 vs 3.62±0.23,P<0.01)。胃癌细胞系circATP2B1表达量均显著低于GES-1细胞(P<0.01),其中以HS-746T细胞的表达量最低(P<0.01)。与对照组相比,实验组HS-746T细胞的增殖活性显著降低(P<0.05),侵袭能力显著下降(P<0.01)。生物信息学和双荧光素酶报告基因实验显示circATP2B1可靶向结合miR-452-5p(P<0.01),miR-452-5p可靶向结合原钙黏附蛋白9(PCDH9)(P<0.01)。与对照组比较,实验组HS-746T细胞miR-452-5p表达显著下降(1.00±0.04 vs 0.24±0.05,P<0.01),PCDH9基因表达显著上升(P<0.01)。结论circATP2B1在胃癌组织和细胞系中低表达,circATP2B1通过靶向结合miR-452-5p正调控PCDH9基因表达,进而降低胃癌HS-746T细胞增殖和侵袭能力。
文摘目的探讨白三烯受体拮抗剂(leukotriene receptor antagonists,LTRA)与ATP结合盒亚家族C1(ATP-binding cassette sub-family C member 1,ABCC1)基因rs119774位点、溶质载体有机阴离子转运蛋白家族成员2B1(solute carrier organic anion transporter family member 2B1,SLCO2B1)基因rs12422149位点的单核苷酸多态性(single nucleotide polymorphism,SNP)治疗汉族儿童支气管哮喘疗效的相关性。方法选取2019年4月至2021年12月于福建中医药大学附属厦门市中医院就诊的4~13岁汉族支气管哮喘患儿100例为研究对象,采用一代测序法对患儿的ABCC1基因rs119774位点、SLCO2B1基因rs12422149位点进行检测,分析比较2个位点的SNP分布情况。入组患儿均应用LTRA进行治疗,分别于治疗前与治疗12周时进行肺通气功能及脉冲震荡功能检测,并评估临床症状控制水平,分析患儿疗效与SNP的相关性。统计学方法采用t检验、χ^(2)检验。结果治疗前与治疗12周后,ABCC1基因rs119774位点CC型哮喘患儿应用孟鲁司特钠第1秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))[(87.0±16.5)与(93.2±15.1)L,t=-2.071,P=0.038]、峰值呼气流速(peak expiratory flow,PEF)[(77.1±16.9)与(86.5±16.6)L/s,t=-3.233,P=0.001]和25%肺活量的呼气流速(forced expiratory flow 25,FEF25)[(69.6±18.8)与(78.1±19.9)L/s,t=-1.985,P=0.047]均有明显提高,脉冲震荡各项指标显著改善(P<0.05)。治疗后SLCO2B1基因rs12422149位点AA型肺功能指标PEF高于治疗前[(79.0±16.0)与(93.0±9.4)L/s,t=-2.547,P=0.011],治疗后GG型肺功能各指标显著高于治疗前(P<0.05)。ABCC1治疗前后控制率[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001];治疗前后SLCO2B1基因rs119774位点AA型、AG型、GG型的控制率分别为[59%(59/100)与78%(78/100),78%(78/100),χ^(2)=20.964,P<0.001]、[53%(8/15)与80%(12/15),93%(14/15)χ^(2)=12.786,P=0.002]与[56%(23/41)与78%(32/41),78%(32/41),χ^(2)=6.583,P=0.037]与[73%(32/44)与77%(34/44),73%(32/44),χ^(2)=6.471,P=0.039],均显著改善。结论LTRA治疗汉族支气管哮喘患儿与ABCC1、SLCO2B1基因SNP的效果存在相关性。
文摘Fexofenadine is useful in various allergic disease treatment.However,the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking.This study aimed to verify the validity of previously proposed genetic factors through fexofenadine population pharmacokinetic modeling and to explore the quantitative correlations affecting the pharmacokinetic variability.Polymorphisms of the organic-anion-transporting-polypeptide(OATP)1B1 and 2B1 have been proposed to be closely related to fexofenadine pharmacokinetic diversity.Therefore,modeling was performed using fexofenadine oral exposure data according to the OATP1B1-and 2B1-polymorphisms.OATP1B1 and 2B1 were identified as effective covariates of clearance(CL/F)and distribution volume(V/F)-CL/F,respectively,in fexofenadine pharmacokinetic variability.CL/F and average steady-state plasma concentration of fexofenadine differed by up to 2.17-and 2.20-folds,respectively,depending on the OATP1B1 polymorphism.Among the individuals with different OATP2B1 polymorphisms,the CL/F and V/F differed by up to 1.73-and 2.00-folds,respectively.Ratio of the areas under the curves following single-and multiple-administrations,and the cumulative ratio were significantly different between OATP1B1-and 2B1-polymorphism groups.Based on quantitative prediction comparison through a model-based approach,OATP1B1 was confirmed to be relatively more important than 2B1 regarding the degree of effect on fexofenadine pharmacokinetic variability.Based on the established pharmacokineticpharmacodynamic relationship,the difference in fexofenadine efficacy according to genetic polymorphisms of OATP1B1 and 2B1 was 1.25-and 0.87-times,respectively,and genetic consideration of OATP1B1 was expected to be important in the pharmacodynamics area as well.This population pharmacometrics study will be a very useful starting point for fexofenadine precision medicine.
文摘目的:研究肥胖小鼠及正常小鼠不同周龄下丘脑组织SH2B1(adapter protein with a Src-homology 2 domain),细胞因子信号转导抑制蛋白3(the suppressor of cytokine signaling-3,SOCS3),蛋白质酪氨酸磷酸酶1B(proteintyrosine phosphatase 1B,PTP1B)和神经肽Y(neturopetide Y,NPY)表达的变化规律及其与血清瘦素及胰岛素水平的关系。方法:选用健康C57BL/6乳鼠制作肥胖动物模型,计算Lee’s指数及稳态模型胰岛素抵抗指数。荧光定量RT-PCR法检测下丘脑SH2B1,SOCS3及PTP1B mRNA表达量,Western印迹检测下丘脑SH2B1和NPY蛋白表达量。结果:与同周龄对照组小鼠相比,肥胖组小鼠下丘脑组织SH2B1 mRNA表达减少,SOCS3及PTP1B mRNA表达增加;Western印迹结果显示:肥胖组小鼠SH2B1蛋白表达水平较对照组下降,NPY表达升高。直线相关分析显示:血清瘦素和血清空腹胰岛素水平与SH2B1 mRNA表达呈负相关,与SOCS3及PTP1B mRNA表达正相关。结论:SH2B1,SOCS3,PTP1B及NPY是肥胖发生、发展过程中的关键因子。
